Next Article in Journal
Disruption of Beta-Cell Mitochondrial Networks by the Orphan Nuclear Receptor Nor1/Nr4a3
Next Article in Special Issue
Roles of CD38 in the Immune Response to Infection
Previous Article in Journal
Shockwaves Suppress Adipocyte Differentiation via Decrease in PPARγ
Previous Article in Special Issue
Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
Open AccessReview

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

1
Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari “Aldo Moro”, 70124 Bari, Italy
2
Department of Biology, University of Bari “Aldo Moro”, 70125 Bari, Italy
3
Department of Biomedical Sciences and Human Oncology, Unit of General Pathology, University of Bari “Aldo Moro”, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(1), 167; https://doi.org/10.3390/cells9010167
Received: 12 December 2019 / Revised: 31 December 2019 / Accepted: 3 January 2020 / Published: 9 January 2020
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients. View Full-Text
Keywords: multiple myeloma; CD38 antigen; daratumumab; drug resistance multiple myeloma; CD38 antigen; daratumumab; drug resistance
Show Figures

Figure 1

MDPI and ACS Style

Saltarella, I.; Desantis, V.; Melaccio, A.; Solimando, A.G.; Lamanuzzi, A.; Ria, R.; Storlazzi, C.T.; Mariggiò, M.A.; Vacca, A.; Frassanito, M.A. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 2020, 9, 167.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop